COVID-19 vaccine effectiveness
(Randomized evidence)
Search studies
Trial | Type | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
---|---|---|---|---|---|---|---|---|
Intervention 1 | Intervention 2 | |||||||
NCT04510207, ChiCTR2000034780 Sinopharm-Beijing Al Kaabi N, JAMA, 2021 Full text Commentary Commentary |
Inactivated virus |
BBIBP-CorV |
Adjuvant |
RCTPhase 3 | Healthy adults free of known COVID-19 or HIV infection at 3 centres in United Arab Emirates and Bahrain | N= 40411 |
Some concerns Details |
|
ChiCTR2000032459 Sinopharm-Beijing Xia S , Lancet, 2021 Full text Commentary |
Inactivated virus |
BBIBP-CorV |
Adjuvant |
RCTPhase 1-2 | Healthy children and adolescents aged 3 to 17 years free from SARS-CoV-2 infection and antibodies at a single centre in China | N= 1008 |
Low Details |
|
ChiCTR2000032459 Sinopharm-Beijing Xia S, Lancet Infect Dis, 2020 Full text Commentary |
Inactivated virus |
BBIBP-CorV 8mcg Day 0 |
Adjuvant |
RCTPhase 2 | Healthy SARS-CoV-2 serology negative adults 18-59 years old in a single centre in China | N= 448 |
Some concerns Details |
|
ChiCTR2000032459 Sinopharm-Beijing Xia S, Lancet Infect Dis, 2020 Full text Commentary |
Inactivated virus |
BBIBP 4mcg |
Placebo |
RCTPhase 1 | Healthy adults SARS-CoV-2 serology negative adults in a single centre in China | N= 192 |
Low Details |